The FDA approved a fixed-dose combination of carbachol and brimonidine tartrate for presbyopia, offering a noninvasive ...

Combining two eye drops that have been on the market for at least 30 years each has earned Tenpoint Therapeutics an FDA ...

Tenpoint Therapeutics’ Yuvezzi brings a combination approach to presbyopia compared to single mechanisms of action offered by once-daily eye drops from Orasis Pharmaceuticals, Lenz Therapeutics, and ...

The biotech also raised $235 million in debt and equity funding to support marketing of the drop, which it claims to be an ...

The FDA approved Yuvezzi, an eye drop for the treatment of presbyopia, with broad U.S. availability expected in the second quarter, according to a press release from Tenpoint Therapeutics. Yuvezzi ...

Once-daily carbachol/brimonidine tartrate significantly improves aging-related vision loss ...

YUVEZZI (TM) (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% is a dual-agent eye drop approved by the U.S. Food & Drug Administration (FDA) for the treatment of presbyopia, a ...

The FDA approved carbachol/brimonidine tartrate ophthalmic solution (Yuvezzi) for adults with presbyopia, marking the first ...

Tenpoint Therapeutics announced FDA’s approval of Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% ...

Add Yahoo as a preferred source to see more of our stories on Google. When people get into their 40s and beyond, their close-up vision starts to worsen. For many people, cranking up the font size on a ...

It’s possible to have presbyopia and astigmatism at the same time. Treatments such as prescription contacts or glasses and eye surgery can help correct both conditions. Astigmatism and presbyopia are ...

Tenpoint Therapeutics, Ltd., a global, commercial biotechnology company focused on developing groundbreaking treatments to ...